Conavi Medical Corp. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Executive Summary

• Conavi Medical Corp. filed a preliminary short‑form prospectus with British Columbia, Alberta and Ontario securities regulators for an offering of common shares and/or pre‑funded warrants.
• The offering will be conducted on an agency basis through Bloom Burton Securities Inc., with pricing and size to be negotiated at market; closing is expected around December 12 2025.
• Net proceeds are earmarked primarily for obtaining U.S. FDA 510(k) clearance of the next‑generation Novasight Hybrid system, a limited market release, broader U.S. commercial launch, plus working capital and general corporate purposes.

Key Details

• Offering Structure: Common Shares and/or Pre‑Funded Common Share Purchase Warrants (the “Securities”).
• Agency Arrangement: Bloom Burton Securities Inc. will act as the exclusive agent under a definitive agency agreement to be executed prior to pricing.
• Pricing & Size: To be determined through negotiation with Bloom Burton based on market conditions; no fixed per‑share price disclosed at this time.
• Closing Timeline: Anticipated closing on or about December 12 2025, subject to customary closing conditions and regulatory approvals (including TSXV listing).
• Use of Proceeds:
• Obtain U.S. FDA 510(k) clearance for the next‑generation Novasight Hybrid imaging system.
• Execute a limited market release followed by a broader commercial launch in the United States.
• Provide working capital and other general corporate purposes.
• Regulatory Compliance: Offering to be conducted as a private placement outside Canada where applicable, complying with all relevant securities laws; not registered under U.S. Securities Act and therefore unavailable to U.S. persons absent exemption.
• Access to Prospectus: Preliminary prospectus available free of charge on SEDAR+ (www.sedarplus.ca) or directly from Bloom Burton via email ([email protected]) or telephone (416‑640‑7585).

Notable Quotes

(No executive quotes were included in the release.)